Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03650894
Title Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.